“we have China modeled at a single-digit decline for the year.”

In context

“ing. Thanks for squeezing me in. I want to get a little bit closer to understanding what is going on in the Core Lab business. You called out strengths in the U.S., Europe, and Latin America. I think we are moving past some of the China VBP headwinds. Could you characterize the Core Lab trajectory by geography during Q1? Any share gains? Any notable product launches to call out? Robert Ford: You characterized it well. Our sales in China for Core Lab were flat in Q1. Last year, we were down between 15% and 30% every quarter. The teams are making good progress. We are lapping some of the price and volume headwinds, which also contributes. The market dynamics we faced have improved. I am cautious to say it is all lapped because in VBPs you have different phases—regionals, nationals, etc.—but we have China modeled at a single-digit decline for the year. Could we do better than that? It seems like the team has done better in the first quarter, and I hope they will continue. In the U.S., the team has done a fantastic job. Growth rates are high single digits and have been like that for some time. We are renewing contracts at a very high renewal rate—call it 90% plus—and share gains are accelerating. Our win rates are 55% plus; in new business, we are able to win one out of two. Europe is difficult to characterize as one region because of north-south differences, but in general, the business has been mid- to high-single digits pretty reliably. We feel very good about Diagnostics. It has been performing well, with the exception of the impact of VBP in China, and that seems to be lapping. I expect full-year Core Lab growth to be mid-single dig”